China Independent Clinical Laboratory Industry Report 2016-2020: Healthcare Reform Boosts the Rapid Development of Independent Clinical Laboratory Market

Dublin, Sept. 28, 2016 -- Research and Markets has announced the addition of the "China Independent Clinical Laboratory Industry Report, 2016-2020" report to their offering.

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory market size has been growing radically in recent years, reaching about RMB6.5 billion with a year-on-year increase of 37.4% in 2015; it is expected to grow rapidly at a rate of 30%-40% over the next three to five years and report RMB29.2 billion in 2020.

There are approximately 200 independent clinical laboratory enterprises in China, mainly comprehensive diagnostic chains and special diagnostic enterprises. KingMed Diagnostics, Dian Diagnostics, ADICON Clinical Laboratories, and DaAn Health (invested by Da An Gene), which hold a combined market share of 70% and all adopt chain-based model of comprehensive diagnostic services. By the end of 2015, the four enterprises separately had 31, 26, 20 and 8 independent clinical laboratories. While expanding clinical laboratory services actively, all companies are deploying "laboratory +" industrial chain vigorously.

As a titan in China independent clinical laboratory industry, KingMed Diagnostics earned the revenue of RMB2.5 billion to RMB3 billion in 2015 with 40% market share. In the past two years, KingMed Diagnostics has been involved in production and sale of in vitro diagnostic products through acquisitions and independent R & D; moreover, it has made layout on "laboratory + Internet" services by acquiring GoHeath (Guangzhou Jinzhun), access to Tmall's online pharmacies, etc..

Key Topics Covered:

1. Overview of Independent Clinical Laboratory

2. Overview of China Independent Clinical Laboratory Industry
2.1 Policy Environment
2.2 International Market
2.3 Development
2.4 Competitive Landscape

3. Upstream and Downstream Markets of China Independent Clinical Laboratory Industry
3.1 Upstream Market
3.2 Downstream Market
3.2.1 Independent Clinical Laboratory Market Sees Huge Capacity
3.2.2 Healthcare Reform Boosts the Rapid Development of Independent Clinical Laboratory Market
3.2.3 Demand Diversification Promotes the Upgrading of Independent Clinical Laboratory Industry
3.2.4 Healthcare Demand Growth Propels the Independent Clinical Laboratory Forward Faster
3.2.5 Internet Will Stimulate the Business Model Upgrade of Independent Clinical Laboratory Industry

4. Key Players
4.1 KingMed Diagnostics
4.2 ADICON
4.3 Dian Diagnostics
4.4 DAAN Gene
4.5 Shanghai Labway Clinical Laboratory Co., Ltd.
4.6 NYMPHAVN Biotechnology
4.7 SurExam Bio-Tech Co., Ltd.
4.8 Ningbo Medicalsystem Biotechnology Co., Ltd.
4.9 Beijing Lawke Health Laboratory Co., Ltd.
4.10 Beijing Lepu Gene Technology Co.,Ltd.
4.11 Shanghai Biotecan Pharmaceuticals Co., Ltd.
4.12 Jiangsu Superbio Life Science Co., Ltd.
4.13 Other Enterprises

5. Forecast and Outlook
5.1 Industry Development
5.2 Operation Comparison between Enterprises

For more information about this report visit http://www.researchandmarkets.com/research/ppjg87/china_independent

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Laboratory Testing